Combination therapies designed to activate the body’s own T-cells to fight cancer

We are committed to developing immunotherapy treatments to improve the lives of cancer patients across the globe.

Our pipeline is focused on dual-acting immunotherapies that incorporate a T-cell activator and a T-cell co-stimulator into a single injection. Through this, we hope to offer the potential benefits of combination immunotherapy without the need for multiple, independent biologic products.

Combination Therapies Designed to Activate CD8+ T-cells to Fight Cancer

Combination Therapies Indication Pre-clinical Phase 1 Phase 2 Phase 3 Approved Comments
HS-110 (viagenpumatucel-L) NSCLC ImPACT® activation technology in combination with nivolumab and other checkpoint inhibitors TBA
HS-120 NSCLC ComPACT™ activation technology in combination with checkpoint inhibitors TBA
Co-Stimulators
PTX-35 TBA Humanized monoclonal antibody, functional agonist of human TNFRSF25
PTX-15 TBA TL1A-lg fusion protein, functional agonist of human TNFRSF25

HS-110 Phase 2 (DURGA) Clinical Trial

HS-110 is in Phase 2 study for the potential treatment of non-small cell lung cancer (NSCLC), in combination with Bristol-Myers Squibb’s checkpoint inhibitor, nivolumab (Opdivo®). Our therapeutic drug is designed to secrete a wide range of lung cancer-associated antigens bound to gp96 proteins, while activating a broad, T-cell mediated immune response against cancer.

Learn more about our expanded access and compassionate use of investigational medicine